The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells

Journal of Immunology

Volumn 190, Issue 3, 2013, Pages 1372-1379

  Vernon, Philip J ^a   Loux, Tara J ^a   Schapiro, Nicole E ^a   Kang, Rui ^a   Muthuswamy, Ravi ^a   Kalinski, Pawel ^a   Tang, Daolin ^a   Lotze, Michael T ^a   Zeh, Herbert J ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; MACROPHAGE DERIVED CHEMOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CARCINOGENESIS; CELL INFILTRATION; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MICROENVIRONMENT; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PATTERN RECOGNITION; PHENOTYPE; PRIORITY JOURNAL; SUPPRESSOR CELL;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION, NEOPLASTIC; CHEMOKINES; COCARCINOGENESIS; DISEASE PROGRESSION; GENES, RAS; HYPERPLASIA; IMMUNE TOLERANCE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYELOID CELLS; PANCREAS; PANCREATIC NEOPLASMS; RECEPTORS, IMMUNOLOGIC; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84872718513     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201151     Document Type: Article

References (42)

1. Jemal, A., R. Siegel, J. Xu, and E. Ward. 2010. Cancer statistics, 2010. CA Cancer J. Clin. 60: 277-300.
2. Siegel, R., E. Ward, O. Brawley, and A. Jemal. 2011. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61: 212-236.
3. Haugk, B. 2010. Pancreatic intraepithelial neoplasia-can we detect early pancreatic cancer? Histopathology 57: 503-514.
4. Ottenhof, N. A., A. N. A. Milne, F. H. M. Morsink, P. Drillenburg, F. J. W. Ten Kate, A. Maitra, and G. J. Offerhaus. 2009. Pancreatic intraepithelial neoplasia and pancreatic tumorigenesis: Of mice and men. Arch. Pathol. Lab. Med. 133: 375-381.
5. Wachsmann, M. B., L. M. Pop, and E. S. Vitetta. 2012. Pancreatic Ductal Adenocarcinoma: A Review of Immunologic Aspects. J. Invest. Med. 60: 643-663 6.
6. Beatty, G. L., E. G. Chiorean, M. P. Fishman, B. Saboury, U. R. Teitelbaum, W. Sun, R. D. Huhn, W. Song, D. Li, L. L. Sharp, et al. 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331: 1612-1616.
7. Kraman, M., P. J. Bambrough, J. N. Arnold, E. W. Roberts, L. Magiera, J. O. Jones, A. Gopinathan, D. A. Tuveson, and D. T. Fearon. 2010. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-a. Science 330: 827-830.
8. Morse, M. A., J. R. Hall, and J. M. Plate. 2009. Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer. Expert Opin. Biol. Ther. 9: 331-339.
9. Porembka, M., J. Mitchem, B. Belt, C.-S. Hsieh, H.-M. Lee, J. Herndon, W. Gillanders, D. Linehan, and P. Goedegebuure. 2012. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol. Immunother. 61: 1373-1385.
10. Ostrand-Rosenberg, S. 2010. Myeloid-derived suppressor cells: More mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 59: 1593-1600.
11. Gabitass, R. F., N. E. Annels, D. D. Stocken, H. A. Pandha, and G. W. Middleton. 2011. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol. Immunother. 60: 1419-1430.
12. Srivastava, M. K., P. Sinha, V. K. Clements, P. Rodriguez, and S. Ostrand-Rosenberg. 2010. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 70: 68-77.
13. Hanson, E. M., V. K. Clements, P. Sinha, D. Ilkovitch, and S. Ostrand-Rosenberg. 2009. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J. Immunol. 183: 937-944.
14. Tartour, E., H. Pere, B. Maillere, M. Terme, N. Merillon, J. Taieb, F. Sandoval, F. Quintin-Colonna, K. Lacerda, A. Karadimou, et al. 2011. Angiogenesis and immunity: A bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 30: 83-95.
15. Lechner, M. G., C. Megiel, S. M. Russell, B. Bingham, N. Arger, T. Woo, and A. L. Epstein. 2011. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J. Transl. Med. 9: 90.
16. Ueha, S., F. H. W. Shand, and K. Matsushima. 2011. Myeloid cell population dynamics in healthy and tumor-bearing mice. Int. Immunopharmacol. 11: 783-788.
17. Clark, C. E., S. R. Hingorani, R. Mick, C. Combs, D. A. Tuveson and R. H. Vonderheide. 2007. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 67: 9518-9527. (Pubitemid 47535942)
18. Sinha, P., C. Okoro, D. Foell, H. H. Freeze, S. Ostrand-Rosenberg, and G. Srikrishna. 2008. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 181: 4666-4675.
19. Turovskaya, O., D. Foell, P. Sinha, T. Vogl, R. Newlin, J. Nayak, M. Nguyen, A. Olsson, P. P. Nawroth, A. Bierhaus, et al. 2008. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 29: 2035-2043.
20. Kang, R., D. Tang, N. E. Schapiro, K. M. Livesey, A. Farkas, P. Loughran, A. Bierhaus, M. T. Lotze, and H. J. Zeh. 2010. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ. 17: 666-676.
21. Buchser, W. J., T. C. Laskow, P. J. Pavlik, H.-M. Lin, and M. T. Lotze. 2012. Cellmediated autophagy promotes cancer cell survival. Cancer Res. 72: 2970-2979.
22. Kang, R., T. Loux, D. Tang, N. E. Schapiro, P. Vernon, K. M. Livesey, A. Krasinskas, M. T. Lotze, and H. J. Zeh. 2012. The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc. Natl. Acad. Sci. USA 109: 7031-7036.
23. Weiner, L. M., and M. T. Lotze. 2012. Tumor-cell death, autophagy, and immunity. N. Engl. J. Med. 366: 1156-1158.
24. Gebhardt, C., A. Riehl, M. Durchdewald, J. Németh, G. Furstenberger K. Muller-Decker, A. Enk, B. Arnold, A. Bierhaus, P. P. Nawroth, et al. 2008. RAGE signaling sustains inflammation and promotes tumor development. J. Exp. Med. 205: 275-285. (Pubitemid 351281593)
25. Ichikawa, M., R. Williams, L. Wang, T. Vogl, and G. Srikrishna. 2011. S100A8/ A9 activate key genes and pathways in colon tumor progression. Mol. Cancer Res. 9: 133-148.
26. Cheng, P., C. A. Corzo, N. Luetteke, B. Yu, S. Nagaraj, M. M. Bui, M. Ortiz, W. Nacken, C. Sorg, T. Vogl, et al. 2008. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205: 2235-2249.
27. Liliensiek, B., M. A. Weigand, A. Bierhaus, W. Nicklas, M. Kasper, S. Hofer, J. Plachky, H. J. Grone, F. C. Kurschus, A. M. Schmidt, et al. 2004. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113: 1641-1650. (Pubitemid 39071688)
28. Highfill, S. L., P. C. Rodriguez, Q. Zhou, C. A. Goetz, B. H. Koehn, R. Veenstra, P. A. Taylor, A. Panoskaltsis-Mortari, J. S. Serody, D. H. Munn, et al. 2010. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 116: 5738-5747.
29. Connolly, M. K., J. Mallen-St Clair, A. S. Bedrosian, A. Malhotra, V. Vera, J. Ibrahim, J. Henning, H. L. Pachter, D. Bar-Sagi, A. B. Frey, and G. Miller. 2010. Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor. J. Leukoc. Biol. 87: 713-725.
30. Capuano, G., N. Rigamonti, M. Grioni, M. Freschi, and M. Bellone. 2009. Modulators of arginine metabolism support cancer immunosurveillance. BMC Immunol. 10: 1.
31. Mundy-Bosse, B. L., G. B. Lesinski, A. C. Jaime-Ramirez, K. Benninger, M. Khan, P. Kuppusamy, K. Guenterberg, S. V. Kondadasula, A. R. Chaudhury, K. M. La Perle, et al. 2011. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res. 71: 5101-5110.
32. Leenen, P. J. M., M. F. T. R. de Bruijn, J. S. A. Voerman, P. A. Campbell, and W. van Ewijk. 1994. Markers of mouse macrophage development detected by monoclonal antibodies. J. Immunol. Methods 174: 5-19. (Pubitemid 24297132)
33. Mukaida, N., and T. Baba. 2012. Chemokines in tumor development and progression. Exp. Cell Res. 318: 95-102.
34. Sansone, P., and J. Bromberg. 2012. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J. Clin. Oncol. 30: 1005-1014.
35. Nishikawa, H., and S. Sakaguchi. 2010. Regulatory T cells in tumor immunity. Int. J. Cancer 127: 759-767.
36. Ben-Baruch, A. 2006. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev. 25: 357-371. (Pubitemid 44922355)
37. Wu, L., H. Du, Y. Li, P. Qu, and C. Yan. 2011. Signal transducer and activator of transcription 3 (Stat3C) promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis. Am. J. Pathol. 179: 2131-2141.
38. Mundy-Bosse, B. L., G. S. Young, T. Bauer, E. Binkley, M. Bloomston, M. A. Bill, T. Bekaii-Saab, W. E. Carson, III, and G. B. Lesinski. 2011. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy. Cancer Immunol. Immunother. 60: 1269-1279.
39. Chalmin, F., S. Ladoire, G. Mignot, J. Vincent, M. Bruchard, J.-P. Remy-Martin, W. Boireau, A. Rouleau, B. Simon, D. Lanneau, et al. 2010. Membraneassociated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 120: 457-471.
40. Davé, S. H., J. S. Tilstra, K. Matsuoka, F. Li, R. A. DeMarco, D. Beer-Stolz, A. R. Sepulveda, M. P. Fink, M. T. Lotze, and S. E. Plevy. 2009. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J. Leukoc. Biol. 86: 633-643.
41. Campana, L., L. Bosurgi, M. E. Bianchi, A. A. Manfredi, and P. Rovere-Querini. 2009. Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J. Leukoc. Biol. 86: 609-615.
42. Liang, X., M. E. de Vera, W. J. Buchser, A. Romo de Vivar Chavez, P. Loughran, D. Beer-Stolz, P. Basse, T. Wang, B. van Houten, H. J. Zeh, and M. T. Lotze. 2012. Inhibiting autophagy during interleukin 2 immunotherapy promotes long term tumor regression. Cancer Res. 72: 2791-2801.